Table 8.

Estimates of coefficients for the estimated change in PDD of OROS-MPH (final regression model)

Variable	Change in PDD of OROS-MPH (%)a	95% CI (%)a		p-value
Age at current prescription	0.587	0.527	0.647	<0.0001
Male sex	10.783	9.453	12.113	<0.0001
Expedition year	6.545	6.032	7.057	<0.0001
Drug holidayb	15.165	13.814	16.515	<0.0001
ADHD diagnosis F90.0B	4.037	2.663	5.412	<0.0001
ADHD diagnosis F90.0C	−4.795	−6.945	−2.645	<0.0001
Region: Stockholm	−9.866	−11.422	−8.310	<0.0001
Region: West Sweden	−5.046	−6.768	−3.323	<0.0001
Anxiety	−2.115	−3.737	−0.494	0.0106
Depression	−1.931	−3.767	−0.094	0.0394
Bipolar disorder	−5.791	−8.180	−3.402	<0.0001
Personality disorder	4.803	2.549	7.057	<0.0001
Asperger syndrome	−2.840	−5.151	−0.529	0.0160
Substance use disorder	18.010	16.210	19.810	<0.0001
Add-on medication	18.392	16.867	19.917	<0.0001
Concomitant medication: antipsychotics	5.911	4.299	7.523	<0.0001
Concomitant medication: hypnotics	4.514	3.095	5.933	<0.0001
Concomitant medication: SNRI	1.750	0.108	3.393	0.0367

Notes: F90.0B: ADHD; F90.0C: Activity and attention disturbance; F90.0X: Activity and attention disturbance, unspecified.

^aNorth Sweden and expedition year 2006 used as reference.

^bA gap between observations for a patient in the Prescribed Drug Register exceeding 90 days.

Abbreviations: ADHD, attention-deficit/hyperactivity disorder; OROS-MPH, osmotic release oral system methylphenidate; PDD, dispensed patient daily dose; SNRI, serotonin–norepinephrine reuptake inhibitor.